Benchmark analyst Robert Wasserman lowered the firm’s price target on Intensity Therapeutics (INTS) to $1.50 from $4 and keeps a Speculative Buy rating on the shares after the company reported Q2 results and provided an update on their clinical pipeline. The firm cites recent share dilution for its revised price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS: